比较吗氯贝胺与丙咪嗪治疗印度患者抑郁症的疗效和安全性。
Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients.
机构信息
Additional Professor of Psychiatry, Postgraduate Institute of Medical Education and Research.
出版信息
Indian J Psychiatry. 2005 Apr;47(2):84-8. doi: 10.4103/0019-5545.55951.
BACKGROUND
Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India.
AIM
To compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressive disorder.
METHODS
In this prospective study, patients (n=60) were randomly assigned to treatment with moclobemide or imipramine for 6 weeks. Efficacy of the drugs was assessed by observing the mean change in scores on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Scale (MADRS).
RESULTS
Both the groups showed significant decrease in scores at the end of 6 weeks. Patients who received moclobemide had a better side-effect profile.
CONCLUSION
Moclobemide is an effective antidepressant and is better tolerated than imipramine.
背景
吗氯贝胺是一种苯甲酰胺类药物，属于单胺氧化酶-A 抑制剂（MAO-AI）的新一代药物，属于单胺氧化酶可逆抑制剂（RIMA）。大量研究表明，吗氯贝胺的耐受性良好，与其他抗抑郁药一样有效。迄今为止，尚未有关于其在印度的疗效和耐受性的证据。
目的
比较吗氯贝胺与三环类抗抑郁药丙咪嗪治疗重性抑郁症的疗效和安全性。
方法
在这项前瞻性研究中，将 60 名患者随机分为吗氯贝胺或丙咪嗪治疗 6 周。通过观察汉密尔顿抑郁量表（HDRS）和蒙哥马利-阿斯伯格抑郁量表（MADRS）评分的平均变化来评估药物的疗效。
结果
两组在 6 周结束时均显示出评分的显著下降。接受吗氯贝胺治疗的患者具有更好的副作用特征。
结论
吗氯贝胺是一种有效的抗抑郁药，且耐受性优于丙咪嗪。
Zotero 插件